Clinical trials: Cancer of Lung
Hilus Pulmonary Neoplasms
Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Hilus Pumonis Neoplasms.
- Trial name
- IRE (NCT02430597)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04630015
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer, Non-Small-Cell Lung Cancer
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
This study will evaluate feasibility and acceptability of providing the Dignity Therapy/Life Plan intervention to pancreatic or advanced lung cancer patients presenting for treatment in the outpatient medical oncology setting.
- Trial name
- NCT02132325
- Testing
- Dignity Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer
Stereotactic Precision And Conventional Radiotherapy Evaluation
A randomized phase II study for medically inoperable stage I non-small cell lung cancer where stereotactic body radiotherapy in three fractions to 66 Gy is compared with conventionally fractionated radiotherapy to 70 Gy in 35…
- Trial name
- SPACE (NCT01920789)
- Testing
- Stereotactic radiotherapy, Conventionally fractionated radiotherapy
- Volunteers
- 102 people
- Sponsor
- Ass. Prof. Jan Nyman
Lung Cancer
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
The goal of phase 1 of this clinical research study is to find the highest dose of DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib hydrochloride) to patients with NSCLC.
- Trial name
- NCT01455389
- Testing
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Genprex, Inc.
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Non-Small Cell Lung Cancer
SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost…
- Trial name
- HP-SIB-AHFRT (NCT07823855)
- Testing
- hyperfractionated radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Non-Small-Cell Lung
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06678555
- Testing
- Lorlatinib
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Lung Cancers, Radiation Treatment for Tumors
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
The purpose of this study was to evaluate the effect of immunotherapy combined with spatial fractionation radiotherapy and low dose radiotherapy on the prognosis of patients with advanced lung cancer under specific dose regimens…
- Trial name
- NCT06775678
- Testing
- Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy, Conventional fractionated radiotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners.
- Conditions
- Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm, Partner, Stage III Breast Cancer
- Trial name
- NCT03112668
- Testing
- Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Non-small Cell Lung Cancer, Stage IV
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in…
- Conditions
- Non-small Cell Lung Cancer, Stage IV, Oligometastasis
- Trial name
- CHESS (NCT03965468)
- Testing
- Durvalumab, Carboplatin, Paclitaxel
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 96 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-small Cell Lung Cancer
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with…
- Trial name
- NeoLazer (NCT06268210)
- Testing
- Lazertinib+Pemetrexed+Carboplatin, Lazertinib
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Yonsei University
Carcinoma, Non-Small-Cell Lung
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate [ORR], proportion of patients with complete response [CR] plus partial response [PR]) until 18 weeks…
- Trial name
- NCT02272413
- Testing
- BI 695502, Avastin
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 671 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer, Metastasis
Pembrolizumab + Idelalisib for Lung Cancer Study
This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy.
- Conditions
- Non Small Cell Lung Cancer, Metastasis, Recurrence
- Trial name
- PIL (NCT03257722)
- Testing
- Pembrolizumab, Idelalisib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Asha Nayak
EGFR Mutant Advanced Non-small Cell Lung Cancer
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced…
- Trial name
- NCT05394831
- Testing
- JIN-A02
- Where
- 10 sites in United States, South Korea and 1 more
- Volunteers
- 150 people
- Sponsor
- J Ints Bio
NSCLC
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
This phase Ib study will investigate dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of afatinib and ruxolitinib combination therapy, based on the preclinical data that inhibition of IL-6R/JAK1 signal transmission…
- Trial name
- NCT02145637
- Testing
- Afatinib plus Ruxolitinib combination therapy
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Small-cell Lung Cancer
Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer
Thoracic radiotherapy concurrent with chemotherapy stands for the standard regime for limited staged small cell lung cancer. Involved node radiation（INF） replaced elective node irradiation（ENI） as the more popular since several…
- Trial name
- NCT04500145
- Testing
- SIB-IMRT, routine IMRT
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Small Cell Lung Cancer
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.
- Trial name
- NCT02200757
- Testing
- Aldoxorubicin, Topotecan
- Where
- 29 sites in United States, Hungary and 1 more
- Volunteers
- 135 people
- Sponsor
- ImmunityBio, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer, Colorectal Cancer
- Trial name
- NCT05872867
- Testing
- WM-A1-3389, Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Wellmarker Bio
Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3
Randomised trial of chemotherapy or not before surgery in early resectable stages of NSCLC (IB, IIA, IIB, and IIIA/N2).
- Trial name
- NCT00273507
- Testing
- Carboplatin and Paclitaxel
- Where
- Denmark
- Volunteers
- 270 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet